MediciNova, Inc. (MNOV)


-0.03 (-1.66%)
Symbol MNOV
Price $1.78
Beta 0.909
Volume Avg. 0.10M
Market Cap 87.302M
Shares () -
52 Week Range 1.71-2.71
1y Target Est -
DCF Unlevered MNOV DCF ->
DCF Levered MNOV LDCF ->
ROE -14.14% Sell
ROA -13.90% Sell
Operating Margin -
Debt / Equity 1.03% Neutral
P/E -9.37 Strong Sell
P/B 1.35 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest MNOV news

Dr. Yuichi Iwaki M.D., Ph.D.
NASDAQ Global Market

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.